Simultaneous pancreas and kidney transplant vs. pancreas after kidney transplantation: is one better?

Abstract

Purpose of review: For those with insulin dependent diabetes mellitus and renal failure, both simultaneous pancreas and kidney (SPK) and pancreas after kidney (PAK) transplant can free the recipient of renal replacement and insulin therapies and provide survival advantage over ongoing dialysis and diabetes. Yet, pancreas transplants are notably declining in the United States, particularly for PAK.

Recent findings: Pancreas transplant continues to provide better glycemic control than all present medical therapies. Outcomes for both SPK and PAK also continue to improve, and overall patient survival for both SPK and PAK are similar, excellent, and superior to all other transplant or medical options. SPK is associated with better pancreas allograft survival, but this gap is narrowing for PAK, and the best kidney allograft survival is achieved with living donor renal transplant (LDRTx) and PAK.

Summary: PAK remains a viable and successful treatment for uremia and insulin dependent diabetes, and, particularly when following a LDRTx, can confer the additional benefits associated with LDRTx and preemptive transplant. To achieve insulin and dialysis independence, either LDRTx followed by PAK (if a living donor is available) or SPK should be offered to candidates with appropriate indications.